ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

safimaltib

Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Leukemia, Myeloid, Acute · Lymphoma, Non-Hodgkin, led by Johnson & Johnson.

Drug pageSafimaltib: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 1, since Apr 2, 20194 company-led studies, 1 open or runningNext primary completion: Jan 19, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson41 open or runningphase 1since Apr 2, 2019Apr 2, 2019Jan 19, 2028phase 1 · NCT06788509

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Apr 2, 2019First study: phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellFirst studyNCT03900598 · 226 enrolled · United States, Australia, China and more
  2. Dec 1, 2020Phase 1 study in Lymphoma, Non-HodgkinNCT04657224 · 75 enrolled · United States, Australia, Belgium and more
  3. May 4, 2021Phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellNCT04876092 · 45 enrolled · Denmark, France, Poland and more
  4. Jan 25, 2022Named safimaltibINNProposed as its International Nonproprietary Name in WHO's List 126 · before, JNJ-67856633
  5. Jan 16, 2025Phase 1 study in Leukemia, Myeloid, AcuteNCT06788509 · 120 planned · Australia, Belgium, Denmark and more

Ahead

  1. Jan 19, 2028Primary completion: phase 1 study in Leukemia, Myeloid, AcuteNCT06788509

TargetBeta

MALT1 →read by rule
“An orally bioavailable inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), ”NCIt, by rule

Other programs on MALT1

ProgramCompanyFurthest phaseStudies
CARD11-BCL10-MALT1 Complex Inhibitor XL114ruleDr. Reddy's Laboratoriesphase 12
ZE66-0205ruleeilean-therapeuticsphase 11

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06788509Leukemia, Myeloid, Acute · Australia, Belgium, Denmark and more1By invitationJan 19, 2028120
NCT04876092Leukemia, Lymphocytic, Chronic, B-Cell · Denmark, France, Poland and more1CompletedFeb 13, 202545
NCT04657224Lymphoma, Non-Hodgkin · United States, Australia, Belgium and more1CompletedJan 16, 202575
NCT03900598Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, China and more1CompletedMay 22, 2025226

How it is read

Names in the registry

  • “JNJ-67856633”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.